Dendritic Cells-based Vaccine and Immune Monitoring for Hepatocellular Carcinoma
/in Dendritic Cells, Hepatocellular Carcinoma, International Publications /von 2010-02-28 / Korean J. Physiol. Pharmacol. 2010 Feb;14(1):11-4Dendritic cells pulsed with an anti-idiotype antibody mimicking Her-2/neu induced protective antitumor immunity in two lines of Her-2/neu transgenic mice
/in Breast Cancer, Dendritic Cells, International Publications /von 2010-02-24 / Cell. Immunol. 2010;263(1):9-21Consolidative dendritic cell-based immunotherapy elicits cytotoxicity against malignant mesothelioma
/in Dendritic Cells, International Publications, Malignant Pleural Mesothelioma /von 2010-02-18 / Am. J. Respir. Crit. Care Med. 2010 Jun;181(12):1383-90Potent anti-tumor responses to immunization with dendritic cells loaded with tumor tissue and an NKT cell ligand
/in Dendritic Cells, International Publications /von 2010-02-09 / Immunol. Cell Biol. 2010 Jul;88(5):596-604Generation of tumor-specific T lymphocytes using dendritic cell/tumor fusions and anti-CD3/CD28
/in Dendritic Cells, International Publications /von 2010-02-01 / J. Immunother. 2010 Feb-Mar;33(2):155-66What’s the place of immunotherapy in malignant mesothelioma treatments?
/in Dendritic Cells, International Publications, Malignant Pleural Mesothelioma /von 2010-01-30 / Cell Adh Migr 2010 Jan-Mar;4(1):153-61Presentation of tumour antigens by dendritic cells and challenges faced
/in Dendritic Cells, International Publications /von 2010-01-29 / Curr. Opin. Immunol. 2010 Feb;22(1):137-44Tocotrienols are good adjuvants for developing cancer vaccines
/in Dendritic Cells, International Publications /von 2010-01-06 / BMC Cancer 2010 Jan;10:5Generation of myeloma-specific T cells using dendritic cells loaded with MUC1- and hTERT- drived nonapeptides or myeloma cell apoptotic bodies
/in Dendritic Cells, International Publications, Multiple Myeloma /von 2010-01-01 / Neoplasma 2010;57(5):455-64
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Das IOZK
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- Recent developments in targeting breast cancer stem cells (BCSCs): a descriptive review of therapeutic strategies and emerging therapies
- Neoantigen-targeted dendritic cell vaccination in lung cancer patients induces long-lived T cells exhibiting the full differentiation spectrum
- Individualized Multimodal Immunotherapy (IMI): Scientific Rationale and Clinical Experience from a Single Institution